Partners | ADVAXIS

	National Cancer Institute Gynecologic Oncology Group Advaxis is collaborating with the GOG to conduct a multi-center, Phase 2 clinical trial of ADXS-HPV, our Lm-LLO based immunotherapy targeted to HPV, in patients with recurrent or refractory cervical cancer who have failed prior cytotoxic therapy. This Phase 2 trial is underwritten by GOG and will be conducted by GOG investigators. This patient population is similar to the patient population in the cervical cancer study being conducted in India as well as the patients in the Phase 1 trial of ADXS-HPV.
	University of Pennsylvania School of Veterinary Medicine Advaxis is collaborating with Dr. Nicola Mason at the University of Pennsylvania School of Veterinary Medicine to study the ADXS-HER2 construct for the treatment of canine osteosarcoma in large breed companion dogs.
	Cancer Research UK Cancer Research UK (CRUK), the UK organization dedicated to cancer research, is conducting a clinical trial to investigate the use of ADXS-HPV, our Lm-LLO based immunotherapy targeted to HPV, for the treatment of head and neck cancer. This Phase 1/2 clinical trial will investigate the safety and efficacy of ADXS-HPV in head and neck cancer patients who have previously failed treatment with surgery, radiotherapy and chemotherapy – alone or in combination. The study is to be conducted at 3 sites in the UK (Aintree Hospital at the University of Liverpool, The Royal Marsden Hospital in London, and Cardiff Hospital at the University of Wales).
	Montefiore Medical Center Advaxis is collaborating with Dr. Chandan Guha at the Albert Einstein College of Medicine and Montefiore Medical Center to develop the ADXS-PSA construct for the treatment of prostate cancer.
	National Cancer Institute Vaccine Section Advaxis has a Collaborative Research and Development Agreement (CRADA) with the Vaccine Section of the National Cancer Institute for the development of Advaxis immunotherapies. NCI will use different in vitro and in vivo models to elucidate the effect of our immunotherapies on many different types of immune cells. They will also investigate the mechanisms by which they might reduce immune inhibition that protects tumors from immune attack. The work is intended to enhance the anti-tumor effects of Advaxis immunotherapies and alter the tumor microenvironment, enabling them to be used with other methods of cancer treatment.
	Wistar Institute Advaxis is collaborating with the Wistar Institute to explore the potential of FAP as a target for immune attack and as the basis for the development of an Advaxis immunotherapy. Therapeutically targeting FAP (fibroblast activation protein) might significantly reduce tumor growth, as it has in some mouse studies.
	University of British Columbia Advaxis is collaborating with the laboratory of Dr. Tobias Kollmann at the University of British Columbia to develop Advaxis immunotherapies for the treatment of infectious disease and to develop new dosage forms. Dr. Kollmann is an immunologist and neonatal vaccinologist who has published extensively on the use of Listeria immunotherapies as potential therapeutic agents for the treatment of childhood diseases. Dr. Kollmann will use our proprietary immunotherapy vectors for the development of novel infectious disease applications.